Logo
x

Search

Subscribe Now

Commercialize

I-Mab Entered into a Collaboration with Jumpcan to Develop and Commercialize Eftansomatropin Alfa (TJ101) in Mainland China

I-Mab Entered into a Collaboration with Jumpcan to Develop and Commercialize Eftansomatropin Alfa (TJ101) in Mainland China

  • November 11, 2021
Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

  • October 22, 2021
Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Th...

  • October 21, 2021
Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 for CF

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 f...

  • October 20, 2021
Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US

Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US

  • October 19, 2021
Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countr...

  • October 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.